Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111775 | 0.90 | HSD11B1 (0.53) | HSD11B1L3MBTL1PSIP1MAPTHDAC1 | |
| SCHEMBL7523793 | 0.89 | HSD11B1 (0.51) | HSD11B1L3MBTL1PSIP1MAPTHDAC1 | |
| SCHEMBL27774130 | 0.87 | CYP3A4 (0.46) | HSD11B1L3MBTL1PSIP1MAPTHDAC1 | |
| SCHEMBL6422781 | 0.87 | HSD11B1 (0.50) | HSD11B1L3MBTL1PSIP1MAPTHDAC1 | |
| SCHEMBL12237322 | 0.87 | CA2 (0.53) | HSD11B1L3MBTL1PSIP1MAPTHDAC1 | |
| SCHEMBL787249 | 0.87 | LMNA (0.54) | HSD11B1L3MBTL1PSIP1MAPTHDAC1 | |
| SCHEMBL19657913 | 0.87 | HSD11B1 (0.50) | HSD11B1L3MBTL1PSIP1MAPTHDAC1 | |
| SCHEMBL14336043 | 0.85 | TDP1 (0.59) | HSD11B1L3MBTL1MAPTLMNAPOLB | |
| SCHEMBL27771900 | 0.84 | HSD11B1 (0.53) | HSD11B1L3MBTL1PSIP1MAPTHDAC1 | |
| SCHEMBL16349315 | 0.84 | HSD11B1 (0.47) | HSD11B1L3MBTL1PSIP1MAPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 673 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022016195-A1 | PROCESSES FOR THE PREPARATION OF ARGINASE INHIBITORS AND THEIR SYNTHETIC INTERMEDIATES | INCYTE CORPORATION (US) | 2022-01-20 | — | — | WO | claimed |
| EP-3063164-B1 | SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES | OTSUKA PHARMA CO LTD (JP) | 2018-12-05 | — | — | EP | claimed |
| US-RE46965-E1 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-24 | — | — | US | claimed |
| US-9856225-B2 | Substituted phenazines as antimicrobial agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-01-02 | — | — | US | claimed |
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| US-20150376201-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-31 | — | — | US | claimed |
| US-RE45324-E1 | Intermediates for the preparation of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-06 | — | — | US | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| US-7982060-B2 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-19 | — | — | US | claimed |
| WO-2026107431-A1 | STEREOSELECTIVE SYNTHESIS OF L,2-CIS-2-AMINOGLYCOSIDES | BRANDEIS UNIVERSITY (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12622901-B2 | Compounds for tau protein degradation | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260115280-A1 | VACCINES | ADJUVANCE TECH INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115281-A1 | TRITERPENE SAPONIN ANALOGUES | ADJUVANCE TECH INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12612368-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-0975632-A1 | ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE | Glycodesign Inc. (CA) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999004789-A1 | SUBSTITUTED AURONE DERIVATIVES | PHYTERA, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| WO-1998046602-A1 | ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE | GLYCODESIGN INC. (CA) | 1998-10-22 | — | — | WO | disclosed |
| WO-1997026873-A1 | ANTIMICROBIAL AURONE DERIVATIVES | PHYTERA, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| US-5550246-A | Calicheamicin mimics | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1996007652-A1 | CALICHEAMICIN MIMICS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622901-B2 | Compounds for tau protein degradation | MAPT, UBQLN1, PSEN1 | HSD11B1 2773/4885L3MBTL1 1957/4885PSIP1 1794/4885 |
| US-20150376201-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | CTTN, TEK, FLT1 | HSD11B1 296/4885L3MBTL1 1907/4885PSIP1 2495/4885 |
| US-20260115281-A1 | TRITERPENE SAPONIN ANALOGUES | NR1H2, NR1H3, LSS | HSD11B1 35/4885L3MBTL1 3525/4885PSIP1 4218/4885 |
| US-20260115280-A1 | VACCINES | TLR9, TLR3, TLR7 | HSD11B1 810/4885L3MBTL1 2242/4885PSIP1 4734/4885 |
| US-12612368-B2 | Cancer treatments targeting cancer stem cells | MALT1, BCOR, MCL1 | HSD11B1 222/4885L3MBTL1 134/4885PSIP1 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.